M2Bio Sciences inc, an opportunity of a lifetime?

M2Bio Sciences, Inc | WUHN on OTC (Formely Wuhan General Group) In a stock market that…

Wuhan General Group Signs Manufacturing, Distribution and Sales Agreement with Cafféluxe for local and international distribution of Medspresso™

WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) VISIT WUHN PROFILE HERE MONTREAL, QC / ACCESSWIRE / June…

Wuhan General Group Announces Name Change and Rebranding to M2Bio Sciences

M2Bio Sciences, Inc | MMBS MONTREAL, QC / ACCESSWIRE / June 18, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN)…

Revive Therapeutics Expands Research Partnership for Novel Formulation Development and Clinical Research of Psilocybin with the University of Wisconsin-Madison

TORONTO, June 12, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV),…

The psychedelic market | A little-known and undervalued company ahead of their peers

LAST ALERT MADE MORE THAN 800% ! This article is written and published by The Cannabis Stock…

Revive Therapeutics Provides Update on Discussions with Health Canada in Pre-CTA Meeting

TORONTO, June 09, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV),…

Wuhan General Group | WUHN Strengthens Team with New Appointments

WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) VISIT PROFILE HERE MONTREAL, QC / ACCESSWIRE / June 3,…

Revive Therapeutics Announces Filing of a Pre-CTA Meeting Request with Health Canada and Update on U.S. FDA IND Filing and Phase 3 Clinical Trial Design for Bucillamine in the Treatment of COVID-19

TORONTO, June 03, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV),…

Revive Therapeutics Provides an Update on its Psilocybin-Based Pharmaceutical Program

TORONTO, April 29, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV),…

Revive Therapeutics Partners with Complete Phytochemical Solutions to Advance Research Initiatives for Psilocybin-Based Pharmaceutical Products

TORONTO, April 17, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV),…

Revive Therapeutics Engages Novotech as Asia-Pacific CRO for Bucillamine in the Treatment of Infectious Diseases

TORONTO, April 08, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV),…

Revive Therapeutics Announces Filing of FDA Pre-IND Meeting

TORONTO, April 03, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV),…